NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NVO

Novo Nordisk ADR

Jul 03 • 04:00PM ET

69.17

Dollar change -0.65
Percentage change -0.93	%

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN PFE SNY BMY GSK

| Held by: PPH AVDE DFIC PID APIE WINN OZEM RVER DFAI DFAX

Scroll to Statements

Index	-	P/E	20.52	EPS (ttm)	3.37	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	2.17%
Market Cap	232.84B	Forward P/E	14.70	EPS next Y	4.70	Insider Trans	-	Shs Float	3.37B	Perf Month	-2.45%
Enterprise Value	244.01B	PEG	1.10	EPS next Q	0.93	Inst Own	9.71%	Short Float	0.79%	Perf Quarter	1.36%
Income	15.05B	P/S	5.34	EPS this Y	27.85%	Inst Trans	-4.38%	Short Ratio	2.55	Perf Half Y	-19.32%
Sales	43.59B	P/B	15.31	EPS next Y	16.40%	ROA	26.37%	Short Interest	26.61M	Perf YTD	-19.59%
Book/sh	4.52	P/C	38.70	EPS next 5Y	18.69%	ROE	87.53%	52W High	143.69 -51.86%	Perf Year	-52.43%
Cash/sh	1.79	P/FCF	16.30	EPS past 3/5Y	25.78% 21.74%	ROIC	44.25%	52W Low	57.00 21.35%	Perf 3Y	27.74%
Dividend Est.	1.98 (2.87%)	EV/EBITDA	10.82	Sales past 3/5Y	23.46% 18.15%	Gross Margin	84.33%	Volatility	1.91% 2.14%	Perf 5Y	109.48%
Dividend TTM	1.66 (2.40%)	EV/Sales	5.60	EPS Y/Y TTM	16.36%	Oper. Margin	45.11%	ATR (14)	2.18	Perf 10Y	144.98%
Dividend Ex-Date	Mar 31, 2025	Quick Ratio	0.56	Sales Y/Y TTM	22.74%	Profit Margin	34.52%	RSI (14)	44.66	Recom	2.03
Dividend Gr. 3/5Y	28.20% 21.81%	Current Ratio	0.74	EPS Q/Q	10.76%	SMA20	-5.42%	Beta	0.66	Target Price	97.21
Payout	35.93%	Debt/Eq	0.86	Sales Q/Q	15.81%	SMA50	-0.45%	Rel Volume	0.39	Prev Close	69.82
Employees	76302	LT Debt/Eq	0.70	Earnings	May 07 BMO	SMA200	-21.87%	Avg Volume	10.42M	Price	69.17
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.78% 1.73%	Trades		Volume	4,047,485	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight	$120
Oct-02-23	Initiated	Argus	Buy	$110
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform	$130
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy

Show Previous Ratings

Jul-04-25 01:51PM	PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? (Zacks)
11:45AM	Are You Looking for a High-Growth Dividend Stock? (Zacks)
09:53AM	Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance? (Zacks)
03:22AM	Novo Nordisk Teams With WeightWatchers to Expand Wegovy Access (Insider Monkey)
01:01AM	Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. (Barrons.com)
08:48AM	Loading…
Jul-03-25 08:48AM	Pfizer Trades Above 50-Day Average for a Month: Time to Buy? (Zacks)
Jul-02-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
04:35AM	Is Hims & Hers Stock in Trouble? (Motley Fool)
Jul-01-25 05:45PM	Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note (Zacks)
12:25PM	Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share (CNBC TV)
09:57AM	Amazon Wants More Power (Motley Fool)
06:06AM	How Novo Nordisk misread the US market for its weight loss sensation (Reuters)
Jun-30-25 04:05PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily)
10:27AM	Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised) (Zacks)
09:29AM	Hardman Johnston Global Equity Sold Novo Nordisk (NVO) due to Weak Script Trends (Insider Monkey)
09:00AM	Loading…
09:00AM	Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 11:30AM	Is It Too Late to Buy NVIDIA? (Zacks)
11:20AM	Novo Nordisk announces WeightWatchers collaboration for Wegovy (TipRanks)
11:10AM	NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? (Zacks)
10:10AM	Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed? (Zacks)
10:08AM	AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock (Zacks)
04:53AM	Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover? (Motley Fool)
Jun-26-25 08:33PM	This Weight Loss Partnership Was a Short One (Motley Fool)
02:55PM	Telehealth Firm Pushes Back on Novo Nordisk's Semaglutide Ruling (GuruFocus.com)
01:21PM	Tesla exec. & Musk confidant reportedly ousted, US stocks rise (Yahoo Finance Video)
12:19PM	Micron slips, Meta & AI talent, Novo Nordisk & Weight Watchers (Yahoo Finance Video)
11:12AM	VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 (Zacks)
11:09AM	Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy and prioritize patient safety (PR Newswire)
09:43AM	Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth? (Zacks)
06:19PM	Loading…
Jun-25-25 06:19PM	Novo Nordisk A/S (NVO): A Bull Case Theory (Insider Monkey)
03:09PM	Why Shares in Novo Nordisk Lost Weight Today (Motley Fool)
02:20PM	General Mills earnings, Novo Nordisk stock slips, Micron results (Yahoo Finance Video)
12:20PM	Novo Nordisk A/S (NVO): "How Could They Be So Far Behind?," Wonders Jim Cramer (Insider Monkey)
09:07AM	Novo Nordisk split puts Hims & Hers future in question (Yahoo Finance)
05:43AM	After key conference, here's how the race to a $150 billion weight-loss drug market is shaping up (MarketWatch)
04:09AM	Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment (Insider Monkey)
Jun-24-25 04:06PM	Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership (CNBC TV)
01:04PM	Novo Nordisk terminates collaboration with Hims & Hers Health (TipRanks)
11:58AM	CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication (Zacks)
11:47AM	Analyst Report: Novo Nordisk A/S (Morningstar Research)
11:37AM	Novo Nordisk's $50 Obesity Shot Hits India -- The Drug War Just Got Real (GuruFocus.com)
11:25AM	Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers? (Zacks)
09:20AM	Will CVS Health's Formulary Move Boost Its Weight Management Program? (Zacks)
06:58AM	Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug (Pharmaceutical Technology)
06:30AM	Why Did Hims and Hers Stock Crash on Monday? (Motley Fool)
05:51AM	Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know (Motley Fool)
Jun-23-25 08:09PM	Analyst Report: Novo Nordisk A/S (Morningstar Research) -5.49%
05:45PM	Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know (Zacks)
04:28PM	IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs (Investor's Business Daily)
03:31PM	Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock? (Barchart)
02:50PM	HIMS Stock Crashes 30% in a Day: Time to Buy the Dip? (Zacks)
02:36PM	Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities (GlobeNewswire)
02:29PM	Why Novo Nordisk Stock Is Sinking Today (Motley Fool)
02:06PM	Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Collaboration (Barrons.com)
02:02PM	Novo Nordisk Cuts Wegovy Deal, Triggers Massive Selloff in Hims & Hers (GuruFocus.com)
12:37PM	NovoHims & Hers deal ends, Eli Lilly GLP-1 pill: What to know (Yahoo Finance Video)
12:18PM	Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices (Investopedia)
12:01PM	Eli Lilly seeks green light for weekly insulin after strong trial results (Clinical Trials Arena)
11:53AM	Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More (Investopedia)
11:51AM	Novo Nordisk under pressure, ends deal with Hims & Hers (CNBC TV)
11:39AM	Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal (Yahoo Finance)
11:32AM	Hims & Hers, healthcare stocks, BNY: Trending Tickers (Yahoo Finance Video)
11:25AM	NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A (Zacks)
11:20AM	Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints (Investopedia)
10:07AM	Bulls Shrug Off Iran Strikes, Recover from Initial Oil Jolt (Zacks)
10:05AM	Hims & Hers' stock plunges. Here's why Wegovy parent ended its partnership with the company. (MarketWatch)
09:46AM	Stocks to Watch Monday: Exxon, Chevron, Tesla, Fiserv (The Wall Street Journal)
09:17AM	Novo Nordisk Stock Drops on Weight-Loss Data. Why Investors Have Doubts. (Barrons.com)
08:36AM	Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership (Barrons.com)
08:24AM	Hims & Hers stock falls after Novo Nordisk ends weight loss drug pact (Investing.com)
08:03AM	Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing (PR Newswire)
07:46AM	Novo Nordisk ends Hims & Hers collaboration over Wegovy weight loss drug (Reuters)
Jun-22-25 03:35PM	Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress (GlobeNewswire)
09:02AM	Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects (Reuters)
09:00AM	Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine (GlobeNewswire)
Jun-20-25 07:38PM	Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA (GlobeNewswire) -5.49%
07:34PM	Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 (GlobeNewswire)
12:49PM	How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl (Investor's Business Daily)
10:41AM	London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape (Pharmaceutical Technology)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:31AM	E.l.f. Beauty CEO Buys Up Smucker Stock (Barrons.com)
09:30AM	Ricks Is the King of Pharma, Thanks to Lilly's Zepbound (Barrons.com)
09:28AM	LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet? (Zacks)
08:04AM	McDonald's Is Down, But Long-Term Investors Can Still Take a Bite (MarketBeat)
Jun-19-25 10:23AM	What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? (Zacks)
Jun-18-25 11:45AM	Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now (Zacks)
10:52AM	Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space? (Zacks)
10:22AM	GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold? (Zacks)
09:50AM	Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock (Zacks)
09:00AM	Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:08AM	Exploring CVS' Health Services Segment: A Key Growth Engine for 2025? (Zacks)
07:51AM	Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes (Pharmaceutical Technology)
07:45AM	Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? (Motley Fool)
Jun-17-25 05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
01:48PM	Novo Nordisk Reclaims Top Spot in Europe by Market Value (Insider Monkey)
05:05AM	Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee (Fortune)
Jun-16-25 06:21PM	Why Novo Nordisk Stock Sank by Nearly 4% Today (Motley Fool)
12:35PM	Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do? (Zacks)
12:31PM	Nvidia (NVDA) Teams With Novo Nordisk to Advance AI Drug Discovery (GuruFocus.com)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience